Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28922763 | 0.85 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL15655280 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL1420098 | 0.82 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL20641707 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL1458672 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL1009529 | 0.80 | TSHR (1.00) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL2324062 | 0.80 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL25163091 | 0.79 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL5752771 | 0.79 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL20303941 | 0.79 | KMT2A (0.66) | ALDH1A1MEN1KMT2ATSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659025-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-03-08 | — | — | CN | claimed |
| CN-112110938-A | Compound as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-111808259-A | 3D printing silicone rubber and preparation method and application thereof | 四川大学 | 2020-10-23 | — | — | CN | claimed |
| CN-110066282-B | Pyrazolopyrimidinone compound and preparation method and application thereof | 南开大学 | 2020-07-10 | — | — | CN | claimed |
| CN-122094678-A | AP 2-related kinase 1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4724439-A1 | HETEROARYL DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| EP-4725946-A1 | IRAK4 DEGRADATION AGENT AND USE THEREOF | Guangzhou Unirise Pharmaceutical Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-20260070922-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HAGER BIOSCIENCES, LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4707276-A2 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4499611-B1 | MALT1 MODULATORS AND USES THEREOF | RAREFIED BIOSCIENCES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4692096-A1 | MACROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Prime Gene Therapeutics Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-6444696-B1 | 1-ARYL OR HETEROARYL SUBSTITUTED 5-AMINO-4 CARBONYLPYRAZOLE DERIVATIVES; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-09-03 | — | — | US | disclosed |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-08-01 | — | — | US | disclosed |
| EP-1218346-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-03 | — | — | EP | disclosed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6316466-B1 | Pyrazole derivatives P-38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| WO-2001021591-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-29 | — | — | WO | disclosed |
| EP-1075467-A1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999057101-A1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | ALK, IGF1R, PDGFRB | ALDH1A1 855/4885MEN1 2416/4885KMT2A 2199/4885 |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | MAPK1, MAPK8, MAPKAPK2 | ALDH1A1 1667/4885MEN1 4104/4885KMT2A 3772/4885 |
| US-20260070922-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | OPRK1, OPRD1, HCRTR2 | ALDH1A1 1665/4885MEN1 4298/4885KMT2A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.